What is the incidence of confined placental mosaicism and fetal mosaicism, and what fetal risks are associated with confined placental mosaicism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Incidence and Fetal Risks of Confined Placental Mosaicism

Incidence

Confined placental mosaicism (CPM) occurs in 1-2% of all pregnancies when detected at chorionic villus sampling (CVS), with the vast majority of mosaicism detected at CVS representing CPM rather than true fetal mosaicism. 1

Key Incidence Data:

  • Overall mosaicism at CVS: 1-2% of pregnancies 1
  • Mosaic rare autosomal trisomies (RATs) at CVS: 0.6% 1
  • True fetal mosaicism: Only 2.53% (8 of 316) of mosaic cases detected at CVS are confirmed by amniocentesis 1
  • CPM in term placentae: At least 4.8% when systematically analyzed 2
  • CPM among false-positive cell-free DNA results: 33.3% overall, with highest rates for monosomy X (75.5%) and rare autosomal trisomies (57.9%) 3

The incidence varies substantially by chromosome involved and detection method. After introduction of combined first-trimester screening in 2004, detection of CPM with fetal involvement increased from 9% to 15%, and CPM with adverse outcomes increased from 16% to 27% 4.

Fetal Risks of Confined Placental Mosaicism

CPM is associated with a 2-3 fold increased risk of delivering small-for-gestational-age (SGA) neonates, with the most significant risks occurring with trisomy 16 CPM. 5

Primary Adverse Outcomes:

  • Small-for-gestational-age (SGA):

    • Overall odds ratio: 2.45 (95% CI: 1.23-4.89) 5
    • High-quality studies show OR: 3.65 (95% CI: 2.43-5.57) 5
    • SGA rate in CPM pregnancies: 14% 4
    • 11-fold higher risk specifically for trisomy 16 CPM 5

  • Birthweight below 3rd percentile:

    • Odds ratio: 5.33 (95% CI: 1.19-24.19) 5
    • Significantly increased for trisomy 16 CPM (OR: 11.2) 6

  • Fetal growth restriction (FGR):

    • Observed in 34.0% of CPM cases overall 7
    • 29.1% when excluding trisomy 16 7
    • Associated with lower median birth weight percentiles (20.1 vs 43.5 in controls) 3

  • Preterm birth (<37 weeks):

    • Overall rate: 15% in CPM pregnancies 4
    • 10-fold increased risk for trisomy 16 CPM (OR: 10.2) 6

Chromosome-Specific Risks:

Trisomy 16 CPM carries the highest risk, with strong associations to intrauterine growth retardation, SGA, and preterm delivery 5, 6, 2. For other rare autosomal trisomies excluding trisomy 16, the risk of adverse outcomes is lower but still present, with approximately 22% experiencing adverse outcomes 4.

Important Clinical Considerations:

  • Meiotic origin matters: CPM involving meiotic trisomies shows significantly higher rates of FGR and low birthweight compared to mitotic origins 7

  • CPM type: Type 3 CPM (involving both cytotrophoblast and mesenchyme) shows the highest rates of FGR and low birthweight, though differences between types 1,2, and 3 are not always statistically significant 7

  • Pregnancy-associated plasma protein A (PAPP-A): Lower PAPP-A MoM values are predictive of adverse outcomes in CPM (0.23 MoM in SGA cases vs 0.47 MoM in normal outcomes) 4

  • Uniparental disomy risk: CPM resulting from trisomy rescue can lead to uniparental disomy of imprinted chromosomes, requiring specific follow-up testing 8

Clinical Management Implications:

All pregnancies with confirmed CPM require intensified antenatal surveillance regardless of chromosome type, CPM classification, or trisomy origin 5, 7. This includes serial growth ultrasounds and monitoring for signs of placental insufficiency. The overall risk of adverse outcomes in CPM pregnancies that continue is 22% 4, making close prenatal monitoring essential even when amniocentesis shows a normal fetal karyotype.

References

5
Research

Pregnancy outcome of confined placental mosaicism: meta-analysis of cohort studies.

American journal of obstetrics and gynecology, 2022

6
Research

Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA.

Genetics in medicine : official journal of the American College of Medical Genetics, 2020

Related Questions

What is the incidence of confined placental mosaicism?
Is confined placental mosaicism (CPM) or fetal mosaicism more common?
What is the incidence of confined placental mosaicism (CPM) for trisomy 21?
What is the recommended inpatient treatment regimen for community‑acquired pneumonia?
Do immunoglobulins increase blood viscosity?
What is sitosterolemia?
Should a 37-year-old woman who has not completed the HPV vaccination series receive the human papillomavirus (HPV) vaccine?
Can you provide a personalized nutrition plan via email?
For an oxygen‑dependent patient with severe COPD, chronic cor pulmonale, paroxysmal atrial fibrillation, hypertension, hyperlipidemia, and diabetes who cannot undergo an exercise stress test, what non‑invasive cardiac test is indicated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.